Sustainability Infosheet 2022

Access to medicines

idorsia

Management approach to access

As an engaged member of the healthcare community, we understand our role in helping find solutions to ensure that the innovative treatments discovered, developed and commercialized by Idorsia reach the patients who need them. We are committed to playing our part in supporting patient access to our medicines through a variety of mechanisms, such as engaging with payors, patients and patient groups to understand their needs and develop solutions, and, when appropriate, offering access to our treatments via programs such as our Compassionate Use Program (see below).

Responsibility for ensuring patient access to our medicines lies with Idorsia's Commercial Leadership Team. For each approved product, the Value and Access function develops the access strategy, which is part of the Global Product Strategy – a deliverable resulting from collaboration with the Global Marketing and Global Medical Affairs functions, as well as teams in the local markets and scientific experts from our Drug Discovery and Clinical Development teams.

Access to our approved products

QUVIVIQ™ (daridorexant), our innovative insomnia treatment, is approved in the US, the EU, the UK and Switzerland. As part of our US launch of QUVIVIQ (May 2022) and to help support early patient access, Idorsia is offering a strong copay program, including a free first 30-day prescription.

The launches of QUVIVIQ in Germany and Italy took place in November 2022, making QUVIVIQ the first dual orexin receptor antagonist available to patients suffering from chronic insomnia in Europe. The local teams are actively engaging with reimbursement authorities to provide patients with access to this product.

PIVLAZ® (clazosentan) was launched in Japan in April 2022 for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms in patients after aneurysmal subarachnoid hemorrhage (aSAH). With an innovative mechanism of action and proven efficacy and safety in Japanese patients, PIVLAZ is gaining inclusion in hospital formularies and aSAH treatment protocols and is fully reimbursed by the Japanese healthcare system.

Stakeholder engagement

Our relationships with patients and patient groups, the medical community, and other healthcare organizations continue to be based on transparency, trust and a shared commitment to improve the lives of patients. Throughout the product lifecycle, we are in regular contact with key stakeholders in our target disease areas.

We engage with physicians to better understand the unmet medical need, to inform our clinical trial design and to interpret the results of these trials. We participate in expert meetings, such as medical and scientific conferences, to learn from others and to share clinical trial data and other insights.

Throughout the year, via our social media channels, we publish disease awareness information on the various therapeutic areas we are working on. We aim to help increase the visibility of these diseases and reveal their impact on those who live with them. In particular, we have highlighted the effects on mental health of diseases which do not have visible outward manifestations, such as Fabry disease, insomnia, lupus, etc.

We are also committed to raising awareness of target diseases, even in areas where our treatments have yet to be approved. Our work with patient groups includes not only engaging with them to understand patient needs and concerns, but also combining our efforts to shine a light on the experience of patients.

Examples of our work with patient groups

We have worked closely with the Fabry International Network (FIN) – as well as its member patient associations in Europe, Canada, the US and Australia – throughout our Phase 3 study on Fabry disease, and we are continuing this engagement as we conduct the open-label extension study. Each year, we participate in FIN's Fabry Expert Meetings to exchange information and ideas with both patients and leading scientists in the field, with the aim of improving overall care for patients with this devastating rare disease.

On May 10, 2021 – World Lupus Day – Idorsia hosted its first live chat on Twitter with the UK and European patient groups, to highlight the impact of this condition and the value of patient involvement in research. The live tweet chat with Lupus UK and Lupus Europe brought together the lupus patient community and explored key topics in lupus research.

Read the tweet chat conversation

Drug pricing



Our drug pricing reflects the value that our innovations deliver, generating revenues to fuel the discovery and development of future compounds.

The cycle continues as these new innovations create even more value for the healthcare system, transforming the horizon of therapeutic options to help more patients. To demonstrate meaningful innovation, we develop a value proposition, underpinned by our science and clinical data, to help payors assess the value offered by our treatments compared to existing options. Our ultimate goal is to help patients gain access to our treatments through reimbursement or other coverage arrangements.

Compassionate use

In certain circumstances, Idorsia allows access to investigational drugs through the Discretionary Compassionate Use Program.

Requests (made by a qualified physician) can be sent using the **contact form,** including the investigational treatment name and the patient's disease or condition. Idorsia also assesses other factors to determine whether access can be provided via this program, including available clinical data supporting an acceptable benefit–risk ratio for the proposed use, potential implications for the overall clinical development of the medicine, and the available supply of the requested investigational drug.

Compassionate Use is assessed by a group of Idorsia stakeholders with ultimate decision-making and approval authority under the responsibility of our Chief Medical Officer.

About this report

Company profile

Headquartered in Allschwil, Switzerland – a European biotech hub – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. The company has an experienced team of over 1,300 highly qualified professionals covering all disciplines from bench to bedside, and commercial operations in Europe, Japan, and the US – the ideal constellation for bringing innovative medicines to patients.

We are committed to achieving our ambitious goals in an economically, socially and environmentally responsible manner, and, as the company grows, our commitment to sustainability remains as important as ever.

We have a diversified and balanced clinical development pipeline covering multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases. Two Idorsia products are commercially available – QUVIVIQ™ (daridorexant) in the US and Europe, and PIVLAZ® (clazosentan) in Japan.

Idorsia Ltd is the Group's holding and finance company, with 14 subsidiaries across Europe, Asia and the US. Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017.

About our sustainability reporting

The information contained in this info sheet covers the period from January 1, 2020 to December 31, 2022 and pertains to all significant locations of operation. In the context of its sustainability reporting, Idorsia considers significant locations of operation to be those with more than 20 permanent employees. Currently, this includes locations in Switzerland, the US and Japan. Any deviations from this reporting framework are indicated on a case-by-case basis.

The content of our sustainability reporting is aligned with the results of a materiality assessment and references the internationally recognized guidelines of the **Global Reporting Initiative (GRI).**

For the full set of ESG info sheets, visit
www.idorsia.com/sustainability

idorsia